Iovance Biotherapeutics (LTS:0JDK) EV-to-Revenue : 3,036.26 (As of May. 06, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Iovance Biotherapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Iovance Biotherapeutics's enterprise value is $3,610.11 Mil. Iovance Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $1.19 Mil. Therefore, Iovance Biotherapeutics's EV-to-Revenue for today is 3,036.26.

The historical rank and industry rank for Iovance Biotherapeutics's EV-to-Revenue or its related term are showing as below:

LTS:0JDK' s EV-to-Revenue Range Over the Past 10 Years
Min: 759.09 Med: 2501.02 Max: 6604.17
Current: 3036.26

During the past 13 years, the highest EV-to-Revenue of Iovance Biotherapeutics was 6604.17. The lowest was 759.09. And the median was 2501.02.

LTS:0JDK's EV-to-Revenue is ranked worse than
97.2% of 1036 companies
in the Biotechnology industry
Industry Median: 7.98 vs LTS:0JDK: 3036.26

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-06), Iovance Biotherapeutics's stock price is $13.72. Iovance Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Therefore, Iovance Biotherapeutics's PS Ratio for today is 2,744.00.

Iovance Biotherapeutics EV-to-Revenue Historical Data

The historical data trend for Iovance Biotherapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iovance Biotherapeutics EV-to-Revenue Chart

Iovance Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

1,579.80

Iovance Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															-	-	5,931.19	1,247.74	1,579.80

Competitive Comparison of Iovance Biotherapeutics's EV-to-Revenue

For the Biotechnology subindustry, Iovance Biotherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Iovance Biotherapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Iovance Biotherapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Iovance Biotherapeutics's EV-to-Revenue falls into.

Iovance Biotherapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Iovance Biotherapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	3610.108	/	1.189
	=	3,036.26

Iovance Biotherapeutics's current Enterprise Value is $3,610.11 Mil.
Iovance Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.19 Mil.

Iovance Biotherapeutics (LTS:0JDK) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Iovance Biotherapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	13.72	/	0.005
	=	2,744.00

Iovance Biotherapeutics's share price for today is $13.72.
Iovance Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

Iovance Biotherapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Iovance Biotherapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Iovance Biotherapeutics (LTS:0JDK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Iovance Biotherapeutics Inc (LTS:0JDK) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

IOVA:USA 2LB:Germany

Address

825 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.iovance.com

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approval and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

Iovance Biotherapeutics (LTS:0JDK) Headlines

No Headlines